Biologics Commonly Used in Cutaneous Crohn's Disease
Retrospective multicenter cohort highlights genital-predominant presentation patterns and frequent combination therapy use in cutaneous Crohn's disease.
By
Andrea Surnit
May 27, 2026
Clinical Scorecard: Biologics Commonly Used in Cutaneous Crohn Disease
At a Glance
Category Detail
Condition Cutaneous Crohn Disease Key Mechanisms Granulomatous skin manifestation associated with Crohn disease. Target Population Pediatric and adult patients with cutaneous Crohn disease. Care Setting Dermatology clinics across nine US academic centers.
Key Highlights
81% of patients were female. 70% had intestinal Crohn disease at the time of CCD diagnosis. Genital involvement was the most common cutaneous presentation, reported in 44% of patients. Tumor necrosis factor alpha inhibitors were the most commonly prescribed agents, used in 85% of treated patients. Study limitations include retrospective design and heterogeneous data collection. Guideline-Based Recommendations
Diagnosis
Diagnosis requires clinical and histopathologic findings consistent with Delphi consensus criteria. Management
Biologic or small-molecule inhibitor therapy was used in 82% of patients. Monitoring & Follow-up
Outcomes categorized as complete clearance, partial clearance, no effect, or worsening based on clinical documentation. Risks
Study limitations include uncontrolled design and frequent use of combination therapy. Patient & Prescribing Data
57 patients with cutaneous Crohn disease identified from 2000 to 2020.
Most patients received combination therapy; single-agent therapy was uncommon.
Clinical Best Practices
Consider tumor necrosis factor alpha inhibitors as first-line therapy. Monitor for treatment efficacy and adjust therapy as needed. Related Resources & Content
